Arrowhead Pharmaceuticals Company Profile (NASDAQ:ARWR)

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ARWR
  • CUSIP:
Key Metrics:
  • Previous Close: $2.15
  • 50 Day Moving Average: $1.96
  • 200 Day Moving Average: $4.39
  • 52-Week Range: $1.20 - $8.22
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.84
  • P/E Growth: -0.59
  • Market Cap: $160.32M
  • Outstanding Shares: 74,569,000
  • Beta: 2.08
Profitability:
  • Net Margins: -1,663.58%
  • Return on Equity: -89.07%
  • Return on Assets: -64.08%
Debt:
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 2.87%
  • Quick Ratio: 2.87%
Additional Links:
Companies Related to Arrowhead Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Arrowhead Pharmaceuticals (NASDAQ:ARWR) (?)
Ratings Breakdown: 5 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $1.80 (16.28% downside)

Analysts' Ratings History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Show:
DateFirmActionRatingPrice TargetDetails
11/30/2016Jefferies Group LLCReiterated RatingHold$5.00 -> $2.00View Rating Details
11/30/2016William BlairDowngradeOutperform -> Market Perform$12.00 -> $2.00View Rating Details
11/30/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$10.00 -> $2.00View Rating Details
11/30/2016Cantor FitzgeraldDowngradeBuy -> Hold$15.00 -> $1.00View Rating Details
11/30/2016Chardan CapitalDowngradeBuy -> Neutral$8.00 -> $2.00View Rating Details
8/5/2015Royal Bank of CanadaReiterated RatingHold$9.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017        
2/6/2017Q117($0.20)($0.17)$13.24 million$4.37 millionViewListenView Earnings Details
8/9/2016Q316($0.37)($0.32)$0.05 million$39.58 millionViewN/AView Earnings Details
5/10/2016Q216($0.37)($0.35)ViewListenView Earnings Details
2/9/2016Q1($0.41)($0.32)ViewN/AView Earnings Details
12/14/2015Q415($0.39)($0.42)ViewListenView Earnings Details
8/4/2015Q315($0.38)($0.27)ViewN/AView Earnings Details
5/11/2015Q214($0.35)($0.33)$110.00 million$43.75 millionViewListenView Earnings Details
2/9/2015Q114($0.34)($0.41)ViewN/AView Earnings Details
11/25/2014Q413($0.24)($0.33)$40.00 millionViewN/AView Earnings Details
8/12/2014Q313($0.22)($0.22)ViewN/AView Earnings Details
5/6/2014($0.20)($0.31)ViewN/AView Earnings Details
2/4/2014Q4($0.18)($0.33)ViewN/AView Earnings Details
12/18/2013Q4($0.23)($0.43)ViewListenView Earnings Details
5/9/2013Q2 2013($0.41)ViewN/AView Earnings Details
2/13/2013Q1 2013($0.33)ViewN/AView Earnings Details
12/20/2012Q4 2012($0.43)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Current Year EPS Consensus Estimate: $-0.49 EPS
Next Year EPS Consensus Estimate: $-0.56 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.44)($0.35)($0.39)
Q2 20163($0.42)($0.37)($0.39)
Q3 20162($0.40)($0.38)($0.39)
Q4 20162($0.34)($0.31)($0.33)
Q1 20171$0.22$0.22$0.22
Q2 20172($0.16)($0.11)($0.14)
Q3 20172($0.13)($0.11)($0.12)
Q4 20172($0.11)($0.10)($0.11)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Insider Ownership Percentage: 4.57%
Institutional Ownership Percentage: 41.41%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/14/2016Douglas B. GivenDirectorSell12,000$6.72$80,640.00View SEC Filing  
8/23/2016Kenneth Allen MyszkowskiCFOSell6,900$8.00$55,200.00View SEC Filing  
8/22/2016Kenneth Allen MyszkowskiCFOSell13,100$8.00$104,800.00View SEC Filing  
12/30/2015Kenneth Allen MyszkowskiCFOSell23,347$6.13$143,117.11View SEC Filing  
10/28/2015Mauro FerrariDirectorBuy400$7.62$3,048.00View SEC Filing  
10/9/2015Mauro FerrariDirectorBuy1,900$6.19$11,761.00View SEC Filing  
1/5/2015David L LewisInsiderSell15,000$8.01$120,150.00View SEC Filing  
10/15/2014Christopher Richard AnzaloneCEOBuy16,000$6.32$101,120.00View SEC Filing  
10/1/2014Charles MckenneyDirectorSell2,500$14.70$36,750.00View SEC Filing  
9/30/2014David L LewisInsiderSell15,000$15.02$225,300.00View SEC Filing  
9/26/2014Douglas B GivenDirectorSell2,000$15.24$30,480.00View SEC Filing  
6/9/2014Charles MckenneyDirectorSell22,000$14.32$315,040.00View SEC Filing  
2/12/2014Kenneth Allen MyszkowskiCFOSell16,000$18.77$300,320.00View SEC Filing  
2/7/2014Edward W FrykmanDirectorSell3,148$15.98$50,305.04View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
DateHeadline
News IconLooking at the Levels for Arrowhead Pharmaceuticals Inc (ARWR) - The Standard (NASDAQ:ARWR)
6milestandard.com - February 24 at 6:01 PM
News IconStock Volatility Review for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - BVN (NASDAQ:ARWR)
bvnewsjournal.com - February 23 at 8:39 PM
News IconArrowhead Pharmaceuticals, Inc. (ARWR) Has Revealed It All In Its Chart - NY Stock News (NASDAQ:ARWR)
nystocknews.com - February 22 at 3:39 PM
News IconMy Watchlist for Tuesday, February 21 (NASDAQ:ARWR)
ac-investor.blogspot.com - February 20 at 8:23 AM
News IconThe Technicals For Arrowhead Pharmaceuticals, Inc. (ARWR) Have Been Dissected (Brutally) - NY Stock News (NASDAQ:ARWR)
nystocknews.com - February 18 at 3:35 PM
finance.yahoo.com logoARROWHEAD PHARMACEUTICALS, INC. Financials (NASDAQ:ARWR)
finance.yahoo.com - February 10 at 4:07 PM
News IconArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Insider Ownership stands at 3.5 - The Newburgh Press (NASDAQ:ARWR)
newburghpress.com - February 9 at 3:47 PM
biz.yahoo.com logoARROWHEAD PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen (NASDAQ:ARWR)
us.rd.yahoo.com - February 8 at 8:52 PM
istreetwire.com logoEye Catching Stocks: CBL & Associates Properties, Inc. (CBL), Arrowhead Pharmaceuticals, Inc. (ARWR), Investors ... - iStreetWire (NASDAQ:ARWR)
istreetwire.com - February 8 at 3:51 PM
finance.yahoo.com logoEdited Transcript of ARWR earnings conference call or presentation 6-Feb-17 9:30pm GMT (NASDAQ:ARWR)
finance.yahoo.com - February 7 at 4:32 PM
us.rd.yahoo.com logoArrowhead Reports Fiscal 2017 First Quarter Results (NASDAQ:ARWR)
us.rd.yahoo.com - February 6 at 8:40 PM
sg.finance.yahoo.com logoArrowhead Research reports 1Q loss (NASDAQ:ARWR)
sg.finance.yahoo.com - February 6 at 8:40 PM
biz.yahoo.com logoQ1 2017 Arrowhead Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:ARWR)
biz.yahoo.com - February 6 at 3:39 PM
News IconArrowhead Pharmaceuticals Inc ARWR Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ARWR)
www.bioportfolio.com - February 2 at 1:51 AM
News IconDelving into Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Prospect Journal (NASDAQ:ARWR)
prospectjournal.com - February 1 at 8:49 PM
News IconIncrease in Volatility Draws Attention to Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Wall Street Beacon (NASDAQ:ARWR)
wsbeacon.com - February 1 at 3:47 PM
finance.yahoo.com logoDrug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on Arrowhead Pharmaceuticals and Jaguar Animal Health (NASDAQ:ARWR)
finance.yahoo.com - February 1 at 3:47 PM
finance.yahoo.com logoArrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results (NASDAQ:ARWR)
finance.yahoo.com - January 30 at 4:41 PM
News IconEquity Rundown: RSI and CCI Check on Arrowhead Research Corp. (ARWR) - Sherwood Daily (NASDAQ:ARWR)
sherwooddaily.com - January 24 at 4:05 PM
News IconMarket Review: Indicator Watch for Arrowhead Research Corp. (ARWR) - Sherwood Daily (NASDAQ:ARWR)
sherwooddaily.com - January 23 at 3:42 PM
News IconEarnings in Full Force, Analysts Take Aim at Arrowhead Research Corporation (NASDAQ:ARWR) - Wall Street Beacon (NASDAQ:ARWR)
wsbeacon.com - January 23 at 3:42 PM
News IconStock Perspective: Arrowhead Research Corporation (NASDAQ:ARWR) Earnings in View - Aiken Advocate (NASDAQ:ARWR)
aikenadvocate.com - January 22 at 3:37 PM
News IconArrowhead Research Corporation (NASDAQ:ARWR) Projected to Achieve EPS Of $0.01 - Stock Observer (NASDAQ:ARWR)
www.thestockobserver.com - January 21 at 3:36 PM
News IconWhat are Analysts Expecting for Arrowhead Research Corporation (NASDAQ:ARWR) Earnings? - Aiken Advocate (NASDAQ:ARWR)
aikenadvocate.com - January 20 at 9:44 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Arrowhead Research Corporation (NASDAQ:ARWR) - Wall Street Beacon (NASDAQ:ARWR)
wsbeacon.com - January 20 at 9:44 PM
News IconTrading Corner: Eye on Technical Levels for Arrowhead Research Corp. (ARWR) - Sherwood Daily (NASDAQ:ARWR)
sherwooddaily.com - January 20 at 9:44 PM
finance.yahoo.com logoRobbins Arroyo LLP: Arrowhead Pharmaceuticals, Inc. (ARWR) Misled Shareholders According to a Recently Filed Class Action (NASDAQ:ARWR)
finance.yahoo.com - January 20 at 9:44 PM
News IconFeatured Stock to Focus: Caesars Entertainment Corporation (NASDAQ:CZR) (NASDAQ:ARWR)
vgtoday.net - January 17 at 9:25 PM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Wall Street Beacon (NASDAQ:ARWR)
wsbeacon.com - January 17 at 4:22 PM
News IconHoning in on Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Prospect Journal (NASDAQ:ARWR)
prospectjournal.com - January 17 at 4:22 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Arrowhead ... - Wall Street Beacon (NASDAQ:ARWR)
wsbeacon.com - January 15 at 3:36 PM
finance.yahoo.com logoIMPORTANT ARWR SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:ARWR)
finance.yahoo.com - January 14 at 8:39 PM
globenewswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class ... - GlobeNewswire (press release) (NASDAQ:ARWR)
globenewswire.com - January 14 at 4:23 AM
4-traders.com logoPomerantz Law Firm Announces the Filing of a Class Action against Arrowhead Pharmaceuticals, Inc. and Certain Officers – ARWR (NASDAQ:ARWR)
www.4-traders.com - January 13 at 9:11 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Arrowhead Pharmaceuticals, Inc. and Certain Officers – ARWR (NASDAQ:ARWR)
finance.yahoo.com - January 13 at 9:11 PM
4-traders.com logoSilence Therapeutics : Minority stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR)
www.4-traders.com - January 13 at 4:09 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 – ARWR (NASDAQ:ARWR)
finance.yahoo.com - January 13 at 4:09 PM
thestreet.com logoThese 3 Biotech Stocks Are Already Moving Wildly on Thursday (NASDAQ:ARWR)
us.rd.yahoo.com - January 12 at 8:40 PM
istreetwire.com logoMomentum Stocks: Arrowhead Pharmaceuticals, Inc. (ARWR), Dynegy Inc. (DYN), Reynolds American Inc. (RAI) - iStreetWire (NASDAQ:ARWR)
istreetwire.com - January 12 at 3:40 PM
News IconStock Running Higher Mid-Session: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Wall Street Beacon (NASDAQ:ARWR)
wsbeacon.com - January 11 at 3:54 PM
News IconArrowhead Research Corporation (NASDAQ:ARWR) Broker Price Targets For The Coming Week (NASDAQ:ARWR)
myhealthbowl.com - January 10 at 8:42 PM
News IconUnder the Microscope We Place Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Prospect Journal (NASDAQ:ARWR)
prospectjournal.com - January 10 at 3:41 PM
News IconArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) hit its 52 Week high of $8.22 on Aug 24, 2016 - The Newburgh Press (NASDAQ:ARWR)
newburghpress.com - January 10 at 3:41 PM
istreetwire.com logoInvestor's Watch List: Monsanto Company (MON), Arrowhead Pharmaceuticals, Inc. (ARWR), Atwood Oceanics, Inc ... - iStreetWire (NASDAQ:ARWR)
istreetwire.com - January 9 at 9:31 PM
trustnet.com logoAcquisition of Minority Stake in Arrowhead (NASDAQ:ARWR)
www.trustnet.com - January 9 at 4:30 PM
streetinsider.com logoArrowhead Research (ARWR) Says It's Had No Discussion on Potential Transaction with Silence (NASDAQ:ARWR)
www.streetinsider.com - January 9 at 4:30 PM
News IconINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class Action Lawsuit & a L... (NASDAQ:ARWR)
ih.advfn.com - January 9 at 4:30 PM
us.rd.yahoo.com logoArrowhead Provides Response to New Minority Shareholder Announcement (NASDAQ:ARWR)
us.rd.yahoo.com - January 9 at 4:30 PM
us.rd.yahoo.com logo5:12 am Arrowhead issues response to new minority shareholder announcement by Silence Therapeutics plc; no discussions about any potential transaction (NASDAQ:ARWR)
us.rd.yahoo.com - January 9 at 4:30 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 – ARWR (NASDAQ:ARWR)
finance.yahoo.com - January 9 at 4:30 PM

Social

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Where is Arrowhead Pharmaceuticals' stock going? Where will Arrowhead Pharmaceuticals' stock price be in 2017?

5 analysts have issued 1-year target prices for Arrowhead Pharmaceuticals' shares. Their predictions range from $1.00 to $2.00. On average, they expect Arrowhead Pharmaceuticals' share price to reach $1.80 in the next twelve months.

When will Arrowhead Pharmaceuticals announce their earnings?

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 8th 2017.

Who owns Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Silence Therapeutics Plc (9.21%), BlackRock, Inc (6.90%), State Street Corp (1.30%), Perceptive Advisors LLC (1.14%), Tudor Investment Corp Et Al (0.41%) and Charlemagne Capital Ltd. (0.14%). Company insiders that own Arrowhead Pharmaceuticals stock include Douglas B Given, Kenneth Allen Myszkowski and Mauro Ferrari.

Who sold Arrowhead Pharmaceuticals stock? Who is selling Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp. Company insiders that have sold Arrowhead Pharmaceuticals stock in the last year include Douglas B Given and Kenneth Allen Myszkowski.

Who bought Arrowhead Pharmaceuticals stock? Who is buying Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Tudor Investment Corp Et Al and Charlemagne Capital Ltd..

How do I buy Arrowhead Pharmaceuticals stock?

Shares of Arrowhead Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Arrowhead Pharmaceuticals stock cost?

One share of Arrowhead Pharmaceuticals stock can currently be purchased for approximately $2.15.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Earnings History Chart

Earnings by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Dividend History Chart

Dividend Payments by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Last Updated on 2/25/2017 by MarketBeat.com Staff